21st Century pharmaceutical collaboration: The value convergence

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

New collaborations pairing drug makers with insurers, health systems, patient groups and technology firms are reconfiguring drug R&D and commercialization. Shared data is shaping drug development and demonstrating health outcomes to create value for patients and industry.

Download report

Key findings for biopharma convergence

  • Purchaser groups are linking administrative claims data with electronic health records to conduct population research – with biopharma collaborators – to better understand important population segments, like patients with more than one chronic disease.
  • Healthcare providers, pushed by new payment incentives, are collaborating with the drug industry to measure the effectiveness of therapies on the patients they treat. Prescribing practices increasingly reflect sophisticated cost/benefit analyses.
  • New entrants are bringing biosensor technology and digital tools to healthcare to help biopharmaceutical companies better understand the lives of patients, and how they change in response to drug intervention.
  • Patient advocacy organizations are creating disease-specific registries for research, and consulting with industry players on clinical trial design and protocols.
  • Proposed legislation such as the 21st Century Cures bill would make it easier for drug companies to promote cost effectiveness data as an additional product attribute.

Contact us

Mike Mentesana

Principal, Health Industries Analytics Leader, PwC US

Follow us